key: cord-0909805-lkx8gaim
authors: Knooihuizen, Sally A.I.; Aday, Ariel; Lee, William M.
title: Ketamine‐Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID‐19
date: 2020-11-23
journal: Hepatology
DOI: 10.1002/hep.31650
sha: 9555e7dde0a55c4e6333ba7e75f2d729acdcf2c3
doc_id: 909805
cord_uid: lkx8gaim

Drug‐induced (secondary) sclerosing cholangitis has recently been observed with a number of agents (1). Ketamine is a remarkably safe anesthetic, providing sedation and analgesia as adjunct to or substitute for more traditional sedative medications. Although prior reports of recreational ketamine abuse have been associated with findings of secondary sclerosing cholangitis (SSC; 2,3), we report here a novel presentation of the syndrome in association with prolonged ketamine use in the intensive care unit.

Drug-induced (secondary) sclerosing cholangitis has recently been observed with a number of agents (1) . Ketamine is a remarkably safe anesthetic, providing sedation and analgesia as adjunct to or substitute for more traditional sedative medications. Although prior reports of recreational ketamine abuse have been associated with findings of secondary sclerosing cholangitis (SSC; 2,3), we report here a novel presentation of the syndrome in association with prolonged ketamine use in the intensive care unit.

A 54-year-old female with type 2 diabetes, hypothyroidism, hypertension, and hyperlipidemia developed severe COVID-19 infection requiring mechanical ventilation for hypoxemic respiratory failure. She was difficult to sedate, requiring hydromorphone, midazolam, and high doses of propofol.

Due to insufficient sedation, ketamine was added. After 15 days of ketamine infusions, she received oral ketamine for an additional five days. Nine days after extubation, she developed a cavitary Staphylococcal pneumonia, requiring re-intubation, and another intravenous ketamine bolus at that time.

Her liver chemistries were normal upon admission. After she became critically ill, she was noted to have a slow but persistent rise in her alkaline phosphatase (Alk P) which peaked at 2,239 U/L 

This article is protected by copyright. All rights reserved Barr virus, and Herpes simplex virus were also ruled out. A low titer of cytomegalovirus (CMV) DNA in serum was detected.

MR cholangiopancreatography at the height of her Alk P elevations showed intrahepatic dilatation with a beaded appearance as well as a dilated common bile duct with distal narrowing (Figure 2A) .

Liver biopsy showed biliary ductular reaction with lobular inflammation and one small non-necrotizing lobular granuloma without viral inclusions ( Figure 2B-C) . Taken together, the imaging and pathologic findings are consistent with a unique form of DILI: ketamine-induced sclerosing cholangitis (KISC).

By hospital day 71, her laboratory values improved, and she was discharged. Three months later, repeat liver enzyme tests in clinic showed continued improvement: Alk P 365, AST 43, ALT 55 U/L. We await repeat MR cholangiopancreatography, which is now scheduled for six months following onset.

Prior case reports have documented KISC in patients after recreational ketamine use (2, 3) . This is the first report of therapeutic use of ketamine causing a similar sclerosing cholangitis picture.

Critically ill patients may develop sclerosing cholangitis following ischemic injury to the biliary tree (4); however, our patient's case is most consistent with ketamine toxicity, ischemic injury being unlikely in the absence of significant hypotension or histologic findings consistent with ischemia. Given that her liver chemistries have continued to improve, we expect that KISC will be transient but currently are awaiting repeat MR cholangiopancreatography.

Our patient highlights an under-recognized side effect of prolonged use of ketamine as an analgesic/sedative in critically ill patients: KISC. The COVID-19 pandemic has resulted in many patients with prolonged critical illness requiring intensive sedation, with ketamine being an alternative when conventional sedation is incomplete. Intensivists and hepatologists need to recognize that KISC can be a side effect of prolonged ketamine exposure. 

This article is protected by copyright. All rights reserved 

Sclerosing cholangitislike changes on magnetic resonance cholangiopancreatography in patients with drug-induced liver injury

Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis

Cholestasis and biliary dilatation associated with chronic ketamine abuse: A case series

Secondary sclerosing cholangitis

This article is protected by copyright. All rights reservedWe are grateful for the diligent efforts of the pulmonary critical care staff at Parkland Memorial Hospital in caring for the innumerable Covid-19 patients, and their consultation regarding this patient.We thank Dr. Zhikai Chi for the representative liver biopsy images.

This article is protected by copyright. All rights reserved